What is the long-term trend for Sanara MedTech Inc.'s cash and cash equivalents, end of period?

Over 5 years (2020 to 2025), Sanara MedTech Inc.'s cash and cash equivalents, end of period has grown at a 105.2% compound annual growth rate (CAGR), from $455.37K to $16.58M.

Sanara MedTech Inc. SMTI Cash and cash equivalents, end of period

Cash and cash equivalents, end of period at other companies

Xtant Medical HoldingsXTNT

——

Other financials

Income statement

See full

Revenue$27.8M+18.6%

Gross profit$25.9M+19.8%

Operating income$2.6M+221%

Net income$459.0K+113%

EPS (diluted)$0.05+112%

Balance sheet

See full

Cash & equivalents$13.6M-34.3%

Total debt$48.4M+8.2%

Total equity$7.0M-80.8%

Total assets$69.3M-28.1%

Cash flow

See full

Operating cash flow-$2.5M-23.3%

CapEx$43.8K-97.5%

Free cash flow-$2.5M+32.6%

Valuation

See full

Market cap$216.18M-9.7%

Enterprise value$250.95M-6.5%

P/S2×-0.5×

Profitability

See full

Gross margin92.9%+1.8pp

Operating margin6.1%+5.1pp

Net margin-31.2%-93.4pp

FCF margin-9.8%-3.5pp

Returns & leverage

See full

Return on equity-153.7%-199pp

Debt / equity6.9×+5.7×

Current ratio2.3×-0.5×

Where this comes from

Reported directly by Sanara MedTech Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The official record: Sanara MedTech Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sanara MedTech Inc.'s cash and cash equivalents, end of period.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sanara MedTech Inc.'s cash and cash equivalents, end of period?: Sanara MedTech Inc. (SMTI) reported cash and cash equivalents, end of period of $13.59M in Q1 2026.
How has Sanara MedTech Inc.'s cash and cash equivalents, end of period changed year-over-year?: Sanara MedTech Inc.'s cash and cash equivalents, end of period decreased by 34.3% year-over-year, from $20.69M to $13.59M.
What is the long-term trend for Sanara MedTech Inc.'s cash and cash equivalents, end of period?: Over 5 years (2020 to 2025), Sanara MedTech Inc.'s cash and cash equivalents, end of period has grown at a 105.2% compound annual growth rate (CAGR), from $455.37K to $16.58M.